Synthego's Strategic Acquisition by Perceptive Advisors
Synthego has achieved a significant milestone in its growth journey by successfully closing the acquisition of its assets by Perceptive Advisors, a well-known investment firm specializing in life sciences. This acquisition marks a pivotal moment for Synthego, as it aligns with its objective of advancing CRISPR technology to support groundbreaking scientific discoveries.
A New Chapter for Synthego
With this transition, Synthego plans to maintain its operations seamlessly. The leadership and dedicated team will remain intact, ensuring clients continue receiving high-quality products and services without interruption. The Synthego brand will also endure, reinforcing its commitment to both research and the development of innovative solutions in the CRISPR space.
CEO's Vision for the Future
Craig Christianson, CEO of Synthego, expressed enthusiasm about this new chapter in a recent statement. He emphasized how this partnership with Perceptive Advisors not only fortifies their financial position but also equips them with enhanced resources necessary for accelerating innovation. This support is likely to facilitate an expanded range of products that will benefit laboratories across the globe.
Empowering Scientific Discovery
Synthego's dedication to empowering scientific discovery remains as strong as ever. The company continues its operations in manufacturing leading-edge guide RNA components in the USA, crucial for CRISPR-based therapies. With recent exciting developments like the launch of GMP-grade SpCas9 and new editing options, Synthego is poised to be at the forefront of genetic engineering.
Collaboration with Perceptive Advisors
Working closely with Perceptive Advisors is viewed as a unique opportunity to elevate Synthego's impact in the life sciences sector. Jason Miller, the Chief Commercial Officer, highlighted that the agreement allows Synthego to enhance its offerings while staying dedicated to supporting its customers' vital research endeavors. This synergy will not only expand their product line but will also help to ensure the provision of reliable and advanced CRISPR solutions.
About Perceptive Advisors
Founded in 1999, Perceptive Advisors is an investment management firm with a primary focus on the life sciences arena. Managed from New York, the firm oversees assets amounting to approximately $7 billion. Their mission revolves around supporting the advancement of healthcare technologies that promise to reshape the future of medicine.
About Synthego
Synthego stands out as a dynamic player in the CRISPR solutions landscape, dedicated to enhancing the pace of life science research and therapeutic progress. By offering a range of innovative CRISPR-engineered products, Synthego empowers researchers to attain unprecedented levels of precision in their experiments, facilitating groundbreaking advancements from academia to clinical applications.
Frequently Asked Questions
What is the significance of Synthego's acquisition by Perceptive Advisors?
This acquisition strengthens Synthego's financial position and enhances its capacity for innovation in CRISPR technology.
Will Synthego continue its current operations?
Yes, Synthego will maintain its operations under the new ownership, ensuring continuity in product and service delivery.
What improvements can clients expect from Synthego post-acquisition?
Clients can look forward to expanded product offerings and improvements in service delivery fueled by enhanced resources.
How does this acquisition impact Synthego's products?
This acquisition is expected to accelerate Synthego's product innovation and expand their range in the CRISPR solutions market.
Where is Synthego's manufacturing facility located?
Synthego manufactures its products, including essential guide RNA components, in the USA, specifically in California.
